MilliporeSigma Invests €130M to Strengthen Manufacturing Capabilities

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a science and technology company, has strengthened its manufacturing capabilities for single-use assemblies, a key technology for the production of Covid-19 vaccines and other therapies, by investing € 130 million in Molsheim, France. The investment is the largest ever in the 50-year history of the site and will create more than 800 jobs by the end of 2028.
 
The expansion will further increase capacity for the manufacturing of single-use assemblies belonging to the Mobius portfolio. The 37,000-sq.-ft. ISO7 clean rooms, administrative building and new logistics warehouse are planned to be operational by the end of 2024, and will gradually ramp up to full production through 2028. In 2021, the Life Science business added a single-use assembly production unit for €25 million. Molsheim is the first site in Europe where the company manufactures the product. Further production sites are located in Danvers, Massachusetts, USA, and Wuxi, China.
 
The manufacturing of single-use assemblies is part of the Process Solutions business, a global provider of products to the biopharmaceutical industry. Merck KGaA, Darmstadt, Germany aims to increase sales to approximately €25 billion by 2025. To achieve its growth targets, the company plans to increase its total investments between 2021 and 2025.
 
Over the next five years, the company will implement investment programs worldwide. Target countries include Germany, France, Switzerland, Ireland, China, and the USA. 
 
“Merck is determined to provide patients in Europeand worldwide with reliable access to vaccines and life-saving therapies,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. “This investment in France is an integral component of our plans to expand our global manufacturing footprint and deliver superior customer value across the globe.”